Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Benzinga Biotech Small Cap Conferences, March 2021
14 slides from Streamex's conference presentation, Mar 25, 2021
Slide 1: BioSig Technologies - Benzinga Biotech Small Cap Conferences
pee BioSig 2ee re! technologies Benzinga Biotech Small Cap Conferences, March 2021 J NASDAQ: BSGM
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new pr
Slide 3: Who We Are
Who We Are — NASDAQ: BSGM EP Tech Market 13.5% CAGR* Global EP Market Expected to be $12.2 Billion by 2026* 34 Patents Issued or Allowed e First Customer is #1 Center by Volume in U.S. Razor & Blade Business Model FDA Cleared Unblinding of clinical data in 2021 expected Data source: MarketWatch Glob
Slide 4: Our Solution
Our Solution * Signal processing platform ¢ Intracardiac signals ¢ Customizable software oe. * Artificial intelligence More Geen better decisions™ BioSig’ symeo.: ascm | 4 technologies
Slide 5: "Secret Sauce"
“Secret Sauce” Physicians Can’t Fix What They Can’t See PURE EP Healthwise and the University of Michigan 121152019,
Slide 6: Market Opportunity - PURE EP
Market Opportunity - PURE EP™ Complex Cardiac Ablation: 13.5% Growth Rate 3 425 EP labs Total Global Addressable Market $2.0 Billion
Slide 7: Expanded Product Adoption, Experience, and a Growing Database
Expanded Product Adoption, Experience, and a Growing Database # PURE EP Procedures by Account #PhysicianUsers Diagnosis # of Cases [Texas Cardiac Arrythmia 271 Persistent AF 150 Institute - Austin Mayo Clinic 116 Paroxysmal AF 176 UNIV of Penn 89 ie 70 Mass General 13 Ischemic VT 18 Deborah Heart &
Slide 8: PURE EP System - Customer Installations
PURE EP™ System — Customer Installations 2 3 a Hospital of the : Gor | 4 > University of Pennsylvania p A 4 \ Bs y Texas Cardiac Arrhythmia Institute svaot-ascu |
Slide 9: Business Model
Business Model Data Sets Modules Service Agreements ER ORE, CLEARLY BioSig’ symeo.: ascm | 9 technologes
Slide 10: Commercialization - Regions and Centers of Excellence
Commercialization — Regions and Centers of Excellence United States Revenue Potential $286 Million Florida 120 EP Programs 240 Labs Texas 220 EP Programs 440 Labs Northeast 175 EP Programs 400 Labs SYMBOL: BSGM 10
Slide 11: Highly Profitable Elective Procedure
Highly Profitable Elective Procedure EP procedures are clinically urgent EP is revenue generating + Delaying procedure increases stroke risk and + CV surgery and invasive cardiology have the highest worsens outcomes net annual revenue compared to all other service lines Median Revenues and Cost per
Slide 12: Clinical Data PURE EP 2.0 Trial
Clinical Data PURE EP™ 2.0 Trial Further establish the safety and effectiveness of the PURE EP™ System Multi-center: Mayo Clinic, Mass General, TCAI Enrollment Goal for the Primary Study Completed Q1, 2021* Data Analysis/Unblinding of Primary Study. Q1, 2021* Primary study abstract submission. Q2, 2
Slide 13: Management Team
Management Team Kenneth L. Londoner, MBA. Steve Chaussy, CPA Julie Stephenson, BSN, MBA Natasha Drapeau John Kowalski Olivier Chaudoir Ewald Riechert sBostong., )Bogaelitse SIEMENS Medtronic OL: BSGM
Slide 14: Value Drivers
Value Drivers * $28 million” in cash on the balance sheet and no debt * Expect to triple the customer base in 2021 * Targeting sequential revenue growth in 2021 ¢ Expect CE mark approval / EU entry 2022 ¢ Launched Al program — Mayo partnership * Expect presentation of data Q3 2021 [nasdaq ‘BSGM ~ te
BioSig Technologies — Benzinga Biotech Small Cap Conferences, March 2021 on 6ix